Cargando…
Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses
Buruli ulcer (BU), caused by Mycobacterium ulcerans, is currently treated with a daily combination of rifampin and either injectable streptomycin or oral clarithromycin. An intermittent oral regimen would facilitate treatment supervision. We first evaluated the bactericidal activity of newer antimic...
Autores principales: | Chauffour, Aurélie, Robert, Jérôme, Veziris, Nicolas, Aubry, Alexandra, Pethe, Kevin, Jarlier, Vincent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494103/ https://www.ncbi.nlm.nih.gov/pubmed/32866170 http://dx.doi.org/10.1371/journal.pntd.0007857 |
Ejemplares similares
-
Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice
por: Chauffour, Aurélie, et al.
Publicado: (2016) -
Sensitivity of Mycobacterium leprae to Telacebec
por: Lahiri, Ramanuj, et al.
Publicado: (2022) -
Structure of mycobacterial CIII(2)CIV(2) respiratory supercomplex bound to the tuberculosis drug candidate telacebec (Q203)
por: Yanofsky, David J, et al.
Publicado: (2021) -
Targeting the Mycobacterium ulcerans cytochrome bc(1):aa(3) for the treatment of Buruli ulcer
por: Scherr, Nicole, et al.
Publicado: (2018) -
Resistance of M. leprae to Quinolones: A Question of Relativity?
por: Veziris, Nicolas, et al.
Publicado: (2013)